Shokravi Arveen, Zargham Hanieh
University of British Columbia, Vancouver, BC, Canada.
SAGE Open Med Case Rep. 2024 Feb 23;12:2050313X241231490. doi: 10.1177/2050313X241231490. eCollection 2024.
Minoxidil was first introduced in the 1970s as an anti-hypertensive medication. Hypertrichosis and scalp hair regrowth were noted by users, and the topical formulation of minoxidil was later approved by the Food and Drug Administration for androgenic alopecia and female pattern hair loss. Since then, minoxidil has been used off-label for various hair loss conditions and cosmetic outcomes. There are a multitude of informal reports on online communities presenting personal anecdotes regarding minoxidil's effectiveness as a facial hair enhancement tool; however, this has been seldom discussed in the literature. In this report, we will present a case of identical twin males, one of which used topical 5% minoxidil for over a year on the beard and mustache area, while the other abstained from using the medication.
米诺地尔在20世纪70年代首次作为一种抗高血压药物被引入。使用者注意到多毛症和头皮毛发再生,后来米诺地尔的局部用制剂被美国食品药品监督管理局批准用于雄激素性脱发和女性型脱发。从那时起,米诺地尔已被用于各种脱发情况和美容效果的非标签用途。在线社区有大量非正式报告,讲述了关于米诺地尔作为面部毛发增强工具有效性的个人轶事;然而,这在文献中很少被讨论。在本报告中,我们将呈现一对同卵双胞胎男性的案例,其中一人在胡须和髭区使用局部5%米诺地尔超过一年,而另一人未使用该药物。